Anat Homepage

We’re working to crack the code on affordability to help make biosimilars accessible to the patients who need them.

At Teva, we don’t believe cost should be a barrier between people and the medicines they need. That’s why
we make more generic medicines than any company in the world. In fact, close to 200 million people across six
continents take a Teva medicine every day. Which creates savings every day. In 2018 alone, our generic medicines
generated savings of $54.6 billion across 18 countries, according to analysis by MGA. 

And, we offer copay assistance programs to lower costs and improve patient access to medications. We're working
to make our biosimilars more affordable, so more patients can access the treatments they need.

We’re working to crack the code on affordability to help make biosimilars accessible to the patients who need them.

At Teva, we don’t believe cost should be a barrier between people and the medicines they need. That’s why
we make more generic medicines than any company in the world. In fact, close to 200 million people across six
continents take a Teva medicine every day. Which creates savings every day. In 2018 alone, our generic medicines
generated savings of $54.6 billion across 18 countries, according to analysis by MGA. 

And, we offer copay assistance programs to lower costs and improve patient access to medications. We're working
to make our biosimilars more affordable, so more patients can access the treatments they need.